Ardelyx, Inc. (ARDX)
Price:
6.56 USD
( + 0.81 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Vertex Pharmaceuticals Incorporated
VALUE SCORE:
8
2nd position
ADMA Biologics, Inc.
VALUE SCORE:
11
The best
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
NEWS
Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions
globenewswire.com
2026-02-24 08:00:00DAYTONA BEACH, Fla. and WALTHAM, Mass.
Ardelyx (NASDAQ:ARDX) Director David Mott Buys 333,333 Shares of Stock
defenseworld.net
2026-02-24 04:48:59Ardelyx, Inc. (NASDAQ: ARDX - Get Free Report) Director David Mott bought 333,333 shares of the business's stock in a transaction on Friday, February 20th. The shares were acquired at an average cost of $5.84 per share, for a total transaction of $1,946,664.72. Following the purchase, the director directly owned 3,302,918 shares in the company, valued
Why Ardelyx's Offensive Strategy Doesn't Move The Needle
seekingalpha.com
2026-02-21 03:25:11Why Ardelyx's Offensive Strategy Doesn't Move The Needle
Ardelyx: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability
seekingalpha.com
2026-02-20 11:12:26Ardelyx, Inc. delivered strong FY 2025 revenue growth, driven by Ibsrela, but missed on earnings due to sharply higher SG&A and R&D costs. Ibsrela's accelerating momentum underpins management's guidance for $410–$430M 2026 revenue and a $1B annual target by 2029, supported by patent protection through 2042. Xphozah revenue is declining and maturing, while heavy operational spend and net losses raise concerns about cost discipline and sustainability.
Ardelyx Lead Drug Growth Fails To Lift Sentiment, Stock Drops
benzinga.com
2026-02-20 06:50:58Ardelyx Inc. (NASDAQ: ARDX) shares are down during Friday's premarket session following a recent financial update for the fourth quarter of 2025.
Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript
seekingalpha.com
2026-02-20 02:44:58Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript
Ardelyx (ARDX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com
2026-02-19 18:31:16Although the revenue and EPS for Ardelyx (ARDX) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ardelyx (ARDX) Reports Break-Even Earnings for Q4
zacks.com
2026-02-19 18:10:15Ardelyx (ARDX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.02 per share a year ago.
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
2026-02-19 16:01:00IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs for new IBSRELA indication and next-generation NHE3 inhibitor launched Company is well capitalized to meet current business objectives Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.
Insights Into Ardelyx (ARDX) Q4: Wall Street Projections for Key Metrics
zacks.com
2026-02-17 10:16:24Besides Wall Street's top-and-bottom-line estimates for Ardelyx (ARDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Short Interest in Ardelyx, Inc. (NASDAQ:ARDX) Declines By 15.0%
defenseworld.net
2026-02-16 02:14:58Ardelyx, Inc. (NASDAQ: ARDX - Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 30th, there was short interest totaling 18,557,299 shares, a decrease of 15.0% from the January 15th total of 21,833,586 shares. Based on an average daily trading volume, of 4,965,903 shares,
Ardelyx (ARDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
zacks.com
2026-02-12 11:05:52Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx (ARDX) Projected to Post Quarterly Earnings on Thursday
defenseworld.net
2026-02-12 04:06:58Ardelyx (NASDAQ: ARDX - Get Free Report) will likely be announcing its Q4 2025 results after the market closes on Thursday, February 19th. Analysts expect Ardelyx to post earnings of $0.02 per share and revenue of $118.0430 million for the quarter. Individuals are encouraged to explore the company's upcoming Q4 2025 earning overview page for the
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
globenewswire.com
2026-02-05 08:00:00WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 19, 2026, at 4:30 p.m.
Ardelyx Receives New Patent for Tenapanor
globenewswire.com
2026-02-03 08:29:00WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
globenewswire.com
2026-01-28 08:29:00WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the first patient has been dosed in ACCEL (ten-03-301), a Phase 3 clinical trial designed to assess the safety and efficacy of IBSRELA® (tenapanor) for the treatment of chronic idiopathic constipation (CIC) in adults.
No data to display
Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions
globenewswire.com
2026-02-24 08:00:00DAYTONA BEACH, Fla. and WALTHAM, Mass.
Ardelyx (NASDAQ:ARDX) Director David Mott Buys 333,333 Shares of Stock
defenseworld.net
2026-02-24 04:48:59Ardelyx, Inc. (NASDAQ: ARDX - Get Free Report) Director David Mott bought 333,333 shares of the business's stock in a transaction on Friday, February 20th. The shares were acquired at an average cost of $5.84 per share, for a total transaction of $1,946,664.72. Following the purchase, the director directly owned 3,302,918 shares in the company, valued
Why Ardelyx's Offensive Strategy Doesn't Move The Needle
seekingalpha.com
2026-02-21 03:25:11Why Ardelyx's Offensive Strategy Doesn't Move The Needle
Ardelyx: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability
seekingalpha.com
2026-02-20 11:12:26Ardelyx, Inc. delivered strong FY 2025 revenue growth, driven by Ibsrela, but missed on earnings due to sharply higher SG&A and R&D costs. Ibsrela's accelerating momentum underpins management's guidance for $410–$430M 2026 revenue and a $1B annual target by 2029, supported by patent protection through 2042. Xphozah revenue is declining and maturing, while heavy operational spend and net losses raise concerns about cost discipline and sustainability.
Ardelyx Lead Drug Growth Fails To Lift Sentiment, Stock Drops
benzinga.com
2026-02-20 06:50:58Ardelyx Inc. (NASDAQ: ARDX) shares are down during Friday's premarket session following a recent financial update for the fourth quarter of 2025.
Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript
seekingalpha.com
2026-02-20 02:44:58Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript
Ardelyx (ARDX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com
2026-02-19 18:31:16Although the revenue and EPS for Ardelyx (ARDX) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ardelyx (ARDX) Reports Break-Even Earnings for Q4
zacks.com
2026-02-19 18:10:15Ardelyx (ARDX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.02 per share a year ago.
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
2026-02-19 16:01:00IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs for new IBSRELA indication and next-generation NHE3 inhibitor launched Company is well capitalized to meet current business objectives Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.
Insights Into Ardelyx (ARDX) Q4: Wall Street Projections for Key Metrics
zacks.com
2026-02-17 10:16:24Besides Wall Street's top-and-bottom-line estimates for Ardelyx (ARDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Short Interest in Ardelyx, Inc. (NASDAQ:ARDX) Declines By 15.0%
defenseworld.net
2026-02-16 02:14:58Ardelyx, Inc. (NASDAQ: ARDX - Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 30th, there was short interest totaling 18,557,299 shares, a decrease of 15.0% from the January 15th total of 21,833,586 shares. Based on an average daily trading volume, of 4,965,903 shares,
Ardelyx (ARDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
zacks.com
2026-02-12 11:05:52Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx (ARDX) Projected to Post Quarterly Earnings on Thursday
defenseworld.net
2026-02-12 04:06:58Ardelyx (NASDAQ: ARDX - Get Free Report) will likely be announcing its Q4 2025 results after the market closes on Thursday, February 19th. Analysts expect Ardelyx to post earnings of $0.02 per share and revenue of $118.0430 million for the quarter. Individuals are encouraged to explore the company's upcoming Q4 2025 earning overview page for the
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
globenewswire.com
2026-02-05 08:00:00WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 19, 2026, at 4:30 p.m.
Ardelyx Receives New Patent for Tenapanor
globenewswire.com
2026-02-03 08:29:00WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
globenewswire.com
2026-01-28 08:29:00WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the first patient has been dosed in ACCEL (ten-03-301), a Phase 3 clinical trial designed to assess the safety and efficacy of IBSRELA® (tenapanor) for the treatment of chronic idiopathic constipation (CIC) in adults.